Irinotecán Hikma

Irinotecan, the active ingredient in Irinotecán Hikma, is a topoisomerase I inhibitor presented as an intravenous formulation for use in oncology patients. It is employed in the treatment of metastatic colorectal cancer and, in combination regimens, small cell lung cancer.

GNH USA supplies Irinotecán Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecán Hikma is used in solid‑tumour oncology, targeting cancers that rely on rapid DNA replication.

Metastatic colorectal cancer: improves disease control and prolongs survival when used in standard chemotherapy protocols. Small cell lung cancer (combined therapy): contributes to tumor response as part of multi‑agent regimens. Adjuvant colorectal cancer (selected protocols): may be incorporated to reduce recurrence risk after surgical resection.

Irinotecán Hikma is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count, increasing infection risk. - Diarrhea: often severe and may require supportive care. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness. - Abdominal pain: discomfort in the stomach area.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils, a medical emergency. - Severe colitis: intense intestinal inflammation leading to dehydration. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Hepatic toxicity: elevated liver enzymes or jaundice. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Hemorrhagic cystitis: bladder inflammation with bleeding.

Before initiating Irinotecán Hikma, clinicians should evaluate patient‑specific risk factors and monitor for known toxicities.

Baseline blood counts: assess neutrophil and platelet levels prior to each cycle. Liver function tests: evaluate hepatic enzymes to adjust dosing if needed. Bowel integrity: ensure no obstruction before administration. Concurrent myelosuppressive agents: avoid overlapping toxicities when possible. Pregnancy and lactation: consider risks versus benefits; use only if clearly indicated. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecán Hikma may interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase SN‑38 exposure. - UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia. - Concurrent myelosuppressive chemotherapy: amplify bone‑marrow suppression. - High‑dose radiation therapy: enhance gastrointestinal toxicity. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce drug effectiveness. - Antidiarrheal agents (e.g., loperamide): may mask early signs of severe diarrhea. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Proton‑pump inhibitors: possible effect on gastric pH and absorption of oral supportive meds. - Herbal supplements (e.g., St. John’s wort): could alter metabolic pathways.